US equities |
GOOGL $285.57 ▼-12.10% GOOG $283.36 ▼-11.97% MSFT $525.15 ▼-1.10% MU $943.34 ▼-4.06% META $631.01 ▲+3.02% NVDA $213.53 ▼-0.86% AMZN $246.57 ▼-3.15% AAPL $349.53 ▲+1.66%
FinancialContent

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

13.80 +0.24 (+1.77%)
Delayed Quote Updated: 12:20 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
MediWound to Report Third Quarter 2026 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
News headline image
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Second Quarter 2026 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report First Quarter 2026 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Files Annual Report on Form 20-F
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Third Quarter 2025 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Second Quarter 2025 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report First Quarter 2025 Financial Results
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 Next >